This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Long-term Survival Benefit Of Liver Transplantation With Respect To Nontransplant Options Opens New Perspectives For Properly Selected Patients With Neuroendocrine Tumors

WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- Up to now, liver transplantation for patients with neuroendocrine tumors of gastroentero-pancreatic (GEP-NET) has been controversial because accepted selection criteria are lacking, benefit in survival is unproven, and allocation of donated liver grafts for these patients still does not rely on reproducible results. Nontransplant treatment options for these patients may prolong survival but are palliative.

Researchers at the Italian National Cancer Institute in Milan examined data from 280 patients who were referred for liver transplant. Of those, 192 were assigned to nontransplant options while 88 were eligible for transplant according to predetermined restrictive criteria. Of those, 42 patients underwent transplantation (mostly with suboptimal grafts) while 46 did not get a liver because of graft unavailability, competitive indications, patients' reasons, etc. The two groups carrying the same tumor burden were compared after being followed-up for 10 years.

Statistical analysis demonstrated a significant propensity for survival advantage for those who had transplantation vs. who had not. Overall survival 5 and 10 years after transplantation was 96.8 and 88.9 percent, respectively. Notably, the survival benefit associated with transplantation in patients receiving a new liver a decade before exceeded 3 years of life gained (38.4 months) with respect to any alternative treatment. According to the authors, this could justify enlisting NET patients for transplantation as Model for End-Stage Liver Disease (MELD) exceptions.

According to Vincenzo Mazzaferro, MD, "The most surprising result was the unprecedented quantification of the magnitude of the transplant benefit in patients with NET selected according to restrictive criteria. Interestingly, the gain in life measured at 5 years from transplant was suboptimal – about 7 months – and barely justified transplant consideration. Conversely, the 3 years and a half gained at the 10 years follow-up interval tells us that the long natural history of liver metastases from NET has impeded until now the appreciation of the proper time interval needed to assess treatment success of a complex therapy such as transplantation."

"Our investigation represents the best possible evidence in favor of transplantation for NET,"  Dr. Mazzaferro concludes. "I believe that the study from Milan gives the best evidence to date supporting the principle that liver replacement may benefit certain categories of patients with liver metastases from NETs. This is unprecedented and has potential for radical changes in the treatment algorithm of patients with this disease and for the liver transplant organization and allocation authorities."

Abstract title:Magnitude of survival benefit after Liver Transplantation (LT) for metastatic neuroendocrine tumors (NET) of gastroentero-pancreatic (GEP) origin

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Washington, November 2-5, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 1 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766. Press releases and all abstracts are available online at www.aasld.org.

Media Contact: Gregory Bologna703/299-9766 gbologna@aasld.orgPress Room: November 1 – 5, 2013Walter E. Washington Convention Center, Washington, DCTelephone: 202-249-4092

Researcher: Vincenzo Mazzaferro, MDEmail: vincenzo.mazzaferro@istitutotumori.mi.it Office: +39-02-23902760Mobile phone: +39-348-0185779

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.

SOURCE American Association for the Study of Liver Diseases (AASLD)

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs